AVDL — Avadel Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $847.44m
- $773.66m
- $169.12m
- 32
- 15
- 36
- 16
Annual cashflow statement for Avadel Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 7.03 | -77.3 | -137 | -160 | -48.8 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | -35.7 | 11.2 | 15.1 | 33 | 19.6 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -14.3 | 3.69 | 24.5 | -3 | -20.3 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -48.7 | -77.3 | -70.3 | -129 | -46.9 |
| Capital Expenditures | -0.098 | -0.026 | -0.716 | 0 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -69.6 | 57 | 80.4 | -50.1 | 51.8 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -69.7 | 56.9 | 79.7 | -50.1 | 51.8 |
| Financing Cash Flow Items | 0 | — | -4.8 | 25.6 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 180 | 0.263 | 14.5 | 135 | 16 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 61.9 | -21 | 23.3 | -42.8 | 20.2 |